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INTRODUCTION
ABSTRACT
INTRODUCTION:
CD56 is a cell adhesion molecule normally expressed in
neural tissue and cytotoxic lymphocytes. Aberrant
expression of CD56 can be seen in various hematologic
malignancies and has been well characterized in acute
myeloid leukemia and plasma cell myeloma. However,
limited and inconsistent data are available regarding
CD56 expression in chronic myeloid neoplasms.

DESIGN:
We reviewed CD56 expression in granulocytes and
monocytes from 81 cases of myeloproliferative neoplasm
(MPN) and 42 cases of myelodysplastic syndrome (MDS).
Forty cases of negative staging bone marrow for lymphoma
were used as negative controls. CD56 expression on
granulocytes and monocytes were analyzed using fourcolor flow cytometry in all the cases. In addition, CD56
expression on granulocytes was analyzed in patients with
series bone marrow samples following treatment and
compared with molecular genetic results.

RESULTS:
In negative control cases, CD56 expression in granulocytes
and monocytes was below 2%. Using 10% as positive
threshold, CD56 was positive on granulocytes in 17% and
positive on monocytes in 37% of all cases. Aberrant CD56
expression can be seen in all subtypes of MPN (ET 6%, PV
13%, MPN-U 18%, CML 19% to PMF 28%) and in high grade
MDS (RCMD 18%, RAEB 27%). CD56 expression was
present more frequently in primary myelofibrosis and high
grade MDS than other types of MDS and MPD. In general,
cases with CD56 expression on granulocytes also had
CD56 expression on monocytes, but monocytes usually
had higher percentage of CD56. Series specimens were
available in 5 cases with positive CD56 expression (2 CML,
1 PMF, 1 PV, 1 NPM-U). CD56 expression correlated with
recurrent disease by bone marrow morphology. Where
BCR/ABL transcript and bone marrow engraftment studies
were available, CD56 reduction correlated with reduced
BCR/ABL transcript and/or recipient cell percentage.

RESULTS

• Diagnosis of Myeloproliferative neoplam (MPN) and myelodysplastic syndromes (MDS) require a combination of analyses
of morphology, immunophenotype, genotype, and clinical
presentation.
• Phenotypic aberrancy in granulocytes, monocytes and erythroid
precursors detected by flow cytometry assists the diagnosis of
these diseases.
• CD56 is an adhesion molecule most often expressed in neural
tissue and in granular lmphocytes.
• Aberrant expression of CD56 has been well characterized in
acute and chronic monocytic leukemia, acute myeloid leukemia
and plasma cell myeloma.
• However, limited and inconsistent data are available regarding
CD56 expression on granulocytes in chronic myeloid neoplasms.
• We analyzed CD56 expression on granulocytes and monocytes
in all subtypes of MPN and MDS. We also investigate the
abnormal CD56 clone in response to therapy

METHOD
• We retrospectively reviewed flow cytometry data from Thomas
Jefferson University Hospital in the past 5 years
– 81 myeloproliferative neoplasms (MPN) (including 27 CMLs, 17 ETs,
8 PVs, 18 PMFs, and 11 MPN-Us)

Figure 2: Positive CD56 expression on granulocytes in MPN and MDS.
(A) CML. (B) ET. (C) PV. (D) PMF. (E)MPN-U. (F) MDS.

– 42 MDS (including 11 RAEB1/2, 26 RCMDs, 3 RCUD/RARS, and 2 MDS-Us).
– Negative controls: 40 bone marrow cases from negative staging bone
marrow for lymphoma.

• CD56 expression on granulocytes and monocytes are analyzed
using 4 color flow cytometry.
– All negative controls: <2% of granulocytes positive for CD56
– Positive: ≥10% of granulocytes positive for CD56
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Figure 6: CD56 Expression Parallels with Recurrent Disease by Bone Marrow
Morphology. (A) CD56 expression changes in a patient with ET and PMF
transformation (B) ET with fibrosis. (C) Primary myelofibrosis, hypocellular
(D) Primary myelofibrosis, hypercellular. (E) CD56 expression changes in a
MPN-U patient F. MPN-U. G and H. Status post bone marrow transplant.

• Serial followup specimens were available in 5 cases with
positive CD56 expression (2 CML, 1 PMF, 1 PV, 1 MPN-U). CD56
expression is correlated with morphology, BCR-ABL quantification
and recipient cell percentage post bone marrow transplant

Table 1: Aberrant CD56 expression in granulocytes
and monocytes in MPN and MDS

CONCLUSIONS:
Aberrant CD56 expression on granulocytes is seen in all
subtypes MPN and high grade MDS. CD56 expression in
MPN correlated with bone marrow morphology, BCR/ABL
transcript, and bone marrow engraftment study following
treatment. Identification of abnormal CD56+ granulocytes
and monocytes is helpful in both the initial diagnosis and
long-term follow up of patients with MPN and MDS.

Figure 1: Negative CD56 expression on granulocytes and monocytes
in normal controls
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Figure 3: Positive CD56 expression on monocytes in MPN and MDS.
(A) CML. (B) ET. (C) PV. (D) PMF. (E)MPN-U. (F) MDS.

CONCLUSIONS
• Aberrant CD56 expression on granulocytes is seen in all
subtypes MPN and high grade MDS.
• CD56 expression is expressed more frequently in primary
myelofibrosis than other types of MPD.
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• CD56 expression in MPN correlates with bone marrow
morphology following treatment.
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• CD56 expression in CML parallels BCR/ABL transcript.
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Figure 4: CD56 Reduction Parallels with Reduced BCR/ABL Transcript in
CML after therapy. (A) Status post bone marrow transplant.
(B) Status post chemotherapy.

• In general, cases with CD56 expression on granulocytes also
have CD56 expression on monocytes, but monocytes usually
have higher percentage of CD56. However, total numbers of
monocytes may be small in MPN cases and analyses of CD56
expression may be difficult.

• CD56 expression in patients who received bone marrow
transplant parallels recipient cell percentage.
Figure 5: CD56 Reduction Parallels with Recipient Cell Percentage in MPN
patients who have received bone marrow transplant. (A) CML patient.
(B) MPN-U patient.

• Identification of abnormal CD56+ granulocytes and monocytes
is helpful in both the initial diagnosis and long-term follow up
of patients with MPN and MDS.

